title: Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients.
abstract: BACKGROUND
  It is common practice to administer acyclovir as prophylaxis to patients with hematologic malignancies during neutropenia; however, effective therapy requires frequent dosing, which is difficult in this setting. Valacyclovir has greater oral bioavailability and requires less frequent dosing.
  
  
  OBJECTIVE
  To evaluate the efficacy and safety of valacyclovir compared with acyclovir.
  
  
  METHODS
  Patients who had been treated with chemotherapy or stem-cell transplantation were randomized to receive acyclovir 400 mg orally 3 times daily (n = 51), valacyclovir 500 mg orally twice daily (n = 48), or valacyclovir 250 mg orally twice daily (n = 52) during neutropenia.
  
  
  RESULTS
  Clinical success, defined as the absence of an active herpes simplex virus (HSV) lesion or asymptomatic viral shedding, was similar between the 3 groups (acyclovir 96%, valacyclovir 500 mg 95%, valacyclovir 250 mg 100%). The overall rates of adverse events were similar in the 3 groups.
  
  
  CONCLUSIONS
  Prophylactic treatment with valacyclovir is an effective and safe alternative to acyclovir for the prevention of HSV reactivation in patients with hematologic malignancies.
authors.affiliation: Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Dawn I
authors.initials: DI
authors.lastname: Warkentin
authors.forename: Joel B
authors.initials: JB
authors.lastname: Epstein
authors.forename: Lara M
authors.initials: LM
authors.lastname: Campbell
authors.forename: Judy G
authors.initials: JG
authors.lastname: Yip
authors.forename: Victoria C
authors.initials: VC
authors.lastname: Cox
authors.forename: Allison
authors.initials: A
authors.lastname: Ransier
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Barnett
authors.forename: Fawziah
authors.initials: F
authors.lastname: Marra
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001682:Biological Availability; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications / Q000628:therapy; D006561:Herpes Simplex / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000150:complications; D016037:Single-Blind Method; D033581:Stem Cell Transplantation / Q000009:adverse effects; D000077483:Valacyclovir; D014633:Valine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D000998:Antiviral Agents; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir